O Shaughnessy Asset Management LLC Has $3.93 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

O Shaughnessy Asset Management LLC grew its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 260.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 248,844 shares of the company's stock after purchasing an additional 179,866 shares during the period. O Shaughnessy Asset Management LLC's holdings in Dr. Reddy's Laboratories were worth $3,929,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. boosted its holdings in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after buying an additional 9,373,412 shares in the last quarter. Aikya Investment Management Ltd boosted its stake in shares of Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after acquiring an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Dr. Reddy's Laboratories by 462.1% in the 4th quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after acquiring an additional 2,313,987 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Dr. Reddy's Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after purchasing an additional 1,977,419 shares during the period. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 1.8 %

Shares of NYSE:RDY traded up $0.23 during mid-day trading on Monday, hitting $12.59. The stock had a trading volume of 4,173,362 shares, compared to its average volume of 1,360,047. The company's 50 day moving average is $13.31 and its 200-day moving average is $14.47. Dr. Reddy's Laboratories Limited has a 12-month low of $12.28 and a 12-month high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a market cap of $10.51 billion, a PE ratio of 20.04 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.